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BACKGROUND and aim: Macrolide antibiotics are
widely used in the treatment of suppurative lung
diseases including cystic fibrosis (CF), the most
common inherited fatal disease in the Caucasian
population. This condition is characterized by sec-
ondary Pseudomonas infection resulting in neutro-
phil infiltration within the airways. The aim of the
study was to investigate the evolution of inflamma-
tory process in CF patients receiving long-term
clarithromycin therapy.
Methods: Twenty-seven CF patients (mean age, 12
years) were enrolled into the study. Beside the basic
therapy the patients were treated with clarithromy-
cin at a dose of 250 mg every other day orally. All
patients were routinely examined every 3 months.
Blood and sputum were collected before clarithro-
mycin treatment and then again 3, 6 and 12 months
after the drug prescription. Cytokine concentrations
(tumor necrosis factor-a, interleukin-8, interleukin-4,
interferon-g) in the sputum and plasma were assayed.
Peripheral blood lymphocyte response to phytohe-
magglutinin was also evaluated.
Results: Clarithromycin treatment resulted in a
marked reduction of the cytokine levels both in the
sputum and plasma specimens. At the same time, the
interferon-g/interleukin-4 ratio has been signifi-
cantly elevated. In addition, a sustained increase of
peripheral blood lymphocyte response to phytohe-
magglutinin was demonstrated. These changes were
associated with a significant improvement of the lung
function.
Conclusions: The beneficial effect of the prolonged
treatment of CF patients with a 14-membered ring
macrolide antibiotic clarithromycin seems to be
associated not only with down-regulation of the
inflammatory response, but also with immunological
changes including the switch from Th2 to Th1 type
response.
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Introduction
Clarithromycin belong to an antibiotic family referred
to as macrolides, which is well known since the
erythromycin introduction into antibacterial therapy.
All macrolides are lactone monocycles, which in-
clude from 12 to 23 atoms of carbon, but molecules
used as a drug have commonly 14, 15 or 16 atoms.
There are numerous reports of 14-membered and 15-
membered ring macrolide antibiotics having anti-
inflammatory activity. It has been suggested that
macrolides affect the migration of neutrophils and
inhibit the neutrophil oxidant burst.
1 4 Furthermore,
macrolides have been shown to impair the produc-
tion of pro-inflammatory cytokines, such as inter-
leukin (IL)-6, IL-8, IL-1b, and tumor necrosis factor
(TNF)-a, by cultured human bronchial epithelial
cells
5,6 and in whole blood.
7 Modification of cytokine
production by macrolides has been explored also in
ex vivo experiments. It was shown in mice that long-
term treatment (42 days) with roxithromycin caused a
significant decrease of IL-1, IL-2 and IL-5 produc-
tion.
8,9 Moreover, there were a marked reduction of
TNF-a, IL-6, and macro phage inflammatory protein-
1a (MIP-a) concentrations in the lung of mice
infected with Mycoplasma pneumoniae after the
course of clarithromycin.
10 For a review see also
Labro
11 and Jaffe ´ and Bush.
12
There is extensive literature on the subject of the
beneficial effect of macrolide antibiotics in patients
with suppurative lung diseases including diffuse
panbronchiolitis (DPB) and cystic fibrosis (CF); the
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111latter is the most common inherited fatal disease in
the Caucasian population. Both conditions are char-
acterized by secondary Pseudomonas infection re-
sulting in neutrophil infiltration within the airways.
The prognosis of DPB has been dramatically im-
proved in recent years. Thus, the 10-year mortality of
80% for this disorder was by chance found to be
reduced to only 10% by the administration of
erythromycin and some other macrolides.
13,14 There
is clinical evidence to support the use of macrolide
antibiotics in CF treatment. A significant increase in
both forced vital capacity (FVC) and forced expira-
tory volume in 1 sec (FEV1) following treatment was
shown.
15 18 Nevertheless, the underlying mechan-
isms are not yet fully understood. Besides the
inflammatory cytokine and oxidant production, other
possible target for these drugs must not be ruled out.
This study aimed to investigate the evolution of
inflammatory process in CF patients receiving long-
term clarithromycin therapy.
Patients and methods
Subjects
Twenty-seven patients (mean age, 12.09 /0.6 years)
from the Cystic Fibrosis Department of the Research
Centre for Medical Genetics (Moscow) were enrolled
into the study. CF was diagnosed by increased
chloride concentrations ( /60 mmol/l) in a sweat
test and typical clinical symptoms of the disease, and/
or detection of mutations in both CFTR alleles. The
patient characteristics are presented in Table 1. The
CFTR genotype in 27 CF patients was homozygous for
DF508 mutation in seven individuals and heterozy-
gous in 10 individuals. Five patients had mutations
other than DF508, and in five cases not one in known
mutations has been revealed. Thirteen individuals
were chronically colonized with the mucoid form of
Pseudomonas aeruginosa. FEV1 and FVC values
averaged 65.79 /4.4 and 76.29 /4.0% predicted, respec-
tively. The patients were treated with basic therapy
(mucolytics, multivitamins, high calorie diet, micro-
spheric enzymes) and clarithromycin (KLACID†;
Abbott Laboratories, Abbott Park, Ill, USA), which
was prescribed in the dose of 250 mg every other day.
In the case of acute pulmonary exacerbation, anti-
bacterial treatment depended on the microbiology
analysis of the sputum. Individuals with P. aeruginosa
infection were treated by cephalosporins of third
generation in combination with aminoglycosids or
ciprofloxacin. The patients were examined before
drug prescription and then again every 3 months.
Subjects with chronic P. aeruginosa infection and
poor lung function (FVC and FEV1B/70% predicted)
were evaluated after a 2-week routine antibiotic
course. The patients who demonstrated relatively
good lung function were examined at a time of well-
being during an ordinary visit to the department.
Table 1. Characteristics of the study patients
Age (years) Sex Mutation P. aeruginosa FVC (% predicted) FEV1 (% predicted)
10 Male DF508/DF508 No 88.9 74.9
13 Female  // / No 103.4 99.4
17 Male DF508/CFTRdele2,3 (21 kb) Yes 82.8 71.8
14 Male  // / No 88.3 74.1
15 Female  //2184insA Yes 57.7 46.5
14 Male DF508/DF508 No 89.3 77.8
11 Female DF508/DF508 Yes 57.5 43.4
16 Male  // / No 89.4 81.8
8 Male DF508/dele?(ex13)* Yes 81.4 74.5
6 Female DF508/DF508 No 111.1 103.6
14 Female DF508/DF508 Yes 48.7 40.3
11 Male W1282R(ex20)/- Yes 63.5 34.6
13 Female DF508/W1282X No 66.6 44.9
11 Female DF508/- Yes 56.0 40.7
16 Male  //394delTT No 54.1 45.4
12 Male DF508/ / Yes 68.3 54.1
7 Female DF508/ / Yes 67.8 64.2
11 Male DF508/CFTRdele2,3 (21 kb) No 78.5 65.9
11 Female  //G542X Yes 32.6 22.9
14 Female  // / Yes 82.8 58.0
8 Male  //3821delT(19ex) Yes 65.7 61.4
16 Female DF508/DF508 No 94.8 91.6
10 Male DF508/ / No 101.2 96.9
15 Female DF508/N1303K Yes 46.9 39.0
11 Male  // / No 117.1 102.8
11 Female DF508/DF508 No 87.2 87.8
10 Female DF508/CFTRdele2,3 (21 kb) No 80.9 76.4
Results of pulmonary function tests (forced expiratory volume in 1 sec and forced vital capacity) are expressed as a percentage of predicted
values for age, sex, and height. * Unidentified deletion in exon 13;  /, an unknown mutation.
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Blood was collected in tubes with heparin (25 IU/ml)
by venopuncture. The sputum samples were placed
into the container with ice and delivered to the
laboratory within 1 h. The weight of each sputum
sample was calculated. The same weight of phos-
phate-buffered saline without Ca
2  and Mg
2  was
added to the sputum sample. The mixture placed on
vortex for 10 sec and then on the rocker for 30 min.
The sample was filtered through a 100 mm filter to
remove mucus. The filtrate has been centrifuged at
400 /g for 10 min at 48C to pellet the cells. The
supernatant has been harvested, aliquoted and stored
at  /608C. Protein concentrations in the samples
were measured by Bradford’s method.
19
Peripheral blood lymphocyte response to
phytohemagglutinin
Heparinized peripheral blood was centrifuged and
plasma was collected, aliquoted and stored at  /608C.
The cell pellet was resuspended in phosphate-
buffered saline and mononuclear cells were isolated
by Ficoll /Verographin density gradient centrifuga-
tion. The cells were washed twice and resuspended
in RPMI-1640 medium supplemented with 10% heat-
inactivated donor horse serum, 2 /10
 3 M HEPES,
2m ML-glutamine, 2.8 /10
 6 M 2-mercaptoethanol,
and 20 mg/ml gentamycin. The cells were cultivated
in flat-bottomed 96-well plates, and contained 5 /
10
4 cells in each well. The final concentration of
phytohemagglutinin (PHA) was 5 mg/ml. The cells
were incubated for 72 h at 378C in a humidified
atmosphere containing 5% CO2. Four hours before
the end of cultivation, each well was pulsed with 40
kBq of [
3H]-thymidine. The cells were harvested with
a cell harvester and counted on a liquid scintillation
counter. Triplicate wells were assayed and the counts
per minute were averaged.
Assay of human leukocyte elastase activity
The method is based on the ability of neutrophil
elastase to interact with the specific chromogenic
substrate N-methoxysuccinyl-ala-ala-pro-val p-nitro
anilide (Sigma, St Louis, MO, USA), forming a colored
complex with maximum of absorbance at 410
nm.
20,21 The standard assay was performed in 1 ml
of a solution containing an aliquot of sputum sample
(10 /20 ml), 0.003 M substrate (100 ml) and 0.1 M Tris
containing 0.5 M NaCl (up to 1 ml) at pH 7.6 /7.8.
Probes were assayed for absorbance every 20 sec
during 3 min at 258C. Then absorbance per minute
was accounted. The amount of elastase was calcu-
lated using the formula:
Elastase activity (U=ml) D410 102=V
where D410 is the absorbance per minute, V is the
volume of the sputum aliquot added, and 102 is a
parameter that includes the extinction coefficient, the
length of light path, and volume of the reaction
mixture. Under this specified condition, 1 U of
human neutrophil elastase activity was that amount
that hydrolyzed 1 nM of substrate per minute. Finally,
the value of neutrophil elastase activity was normal-
ized to the protein content in each sample of the
sputum extract.
Cytokine assays
The TNF-a level in plasma was estimated using
commercially available kit (CYTOKINE, St Peter
sburg, Russia).
TNF-a activity in sputum specimens was deter-
mined by the method of Ruff and Gifford
22 with some
modifications. Briefly, murine fibroblastoma cells
(L929 cell line) were seeded at a density 3 /10
4 cells
per well in 96-well plates in 100 ml of medium 199 to
which 10% heat-inactivated calf bovine serum and
gentamycin had been added. Plates were incubated
at 378C in a humidified atmosphere containing 5%
CO2 until the monolayer formation. After the culture
medium elimination, two-fold serial dilution of the
samples (100 ml of each dilution) and 100 ml of fresh
culture medium with 20 mg/ml of actinomycin D were
added, and further incubated for 18 h at the same
conditions. Supernatants were then removed and
cells stained with 0.2% crystal violet (Sigma). After
washing and drying the plates were finally read at 595
nm on a microplate reader. Human recombinant
TNF-a (Institute of Bioorganic Chemistry, Moscow,
Russia) was used as internal standard. For the
comparison of experimental and calibrating curves
the probit-analysis method was used. The TNF-a
content in the samples was normalized to the protein
content in each sputum sample and expressed in IU/
mg protein (1 IU /13.3 pg).
Plasma and sputum samples were analyzed for
IL-4, IL-8, and IFN-g by enzyme-linked immunosor-
bent assay technique with commercially available kits
(CYTOKINE).
Ethics
The study was approved by the Ethics Committee of
the Research Centre for Medical Genetics. All patients
(or their parents) gave written informed consent to all
parts of the study.
Statistical analysis
The effect of clarithromycin treatment on PHA-
induced peripheral blood lymphocyte proliferation
was evaluated using Student’s t-test. The differences
in annual changes in FEV1 and FVC before and after
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Student’s t-test for paired data. For investigating
differences between cytokine concentrations in the
sputa and in the plasma specimens, statistical analysis
was performed using non-parametric Wilcoxon tests.
Results
Pulmonary function tests
During 1 year before the start of clarithromycin, most
patients had experienced a decline in FEV1 and FVC.
Following the drug treatment a significant increase of
the annual values of FEV1 and FVC has been
observed (Fig. 1).
In situ inflammatory markers
Long-term oral administration of clarithromycin was
associated with a sustained reduction of the sputum
TNF-a level (Fig. 2A). Thus, a marked decrease of the
cytokine concentration was already observed after 3
months of the treatment (median, 3.9 compared with
17.3 IU/mg protein; p /0.05). Sputum TNF-a was
again elevated in the point of ‘6 months’ but its level
remained significantly lower than the initial value
(median, 8.2 IU/mg protein; p /0.02). However, a
marked reduction of the sputum TNF-a has been
found after 1 year of the treatment (median, 0.71 IU/
mg protein; pB/0.001).
The alterations in IL-8 level seemed to be less
dramatic (Fig. 2B). Similar to TNF-a, a decrease in the
cytokine concentration was found after 3 months of
the treatment (median, 2.7 pg/mg of protein; p /
0.03). After a 6-month course of clarithromycin, IL-8
concentrations in the sputa did not significantly differ
from the initial levels (median, 5.94; p /0.13). Never-
theless, there was two-fold reduction of the cytokine
concentration in the end of the study (median, 2.3
pg/mg of protein; p /0.03). It has been noted that
both pro-inflammatory cytokines, TNF-a and IL-8,
demonstrated a marked reduction after 3 months of
the treatment. This effect seems to be related in part
with season fluctuations of in situ inflammatory
markers commonly observed in patients with chronic
lung disease. Indeed, in our study the point of ‘3
months’ fell in June whereas the next sputum
collection was performed in October, a relatively
cold month in Moscow.
Figure 2C illustrates the changes of IFN-g levels in
the sputum specimens. There were no significant
alterations in the cytokine concentrations during 6-
month treatment with clarithromycin (medians for 0,
3, and 6 months, 31.6, 27.5, and 44.7 pg/mg of
protein, respectively). In the same time over 1 year,
the cytokine became undetectable in the sputum
specimens of the most patients.
As can be seen in Figure 2D, the drop of the
sputum IL-4 was most sustained and pronounced.
Thus, a 10-fold decrease of the cytokine concentra-
tion has been demonstrated beginning at the sixth
month of observation (medians for 0, 6, and 12
months, 41.8, 3.0, and 5.9 pg/mg of protein, respec-
tively; both pB/0.01).
We failed to find significant changes both in
neutrophil elastase activity and protein concentration
in the sputum specimens during clarithromycin
treatment (Table 2).
Inflammatory markers in peripheral blood
Figure 3A illustrates changes in plasma IL-4 during
the course of clarithromycin. We found a marked
decrease in the cytokine concentration after 6 months
of the treatment (median, 25.5 compared with 48.5
pg/ml; p /0.002). Over 1 year a 10-fold reduction of
the cytokine level has been shown (median, 3.4 pg/
ml; pB/0.001). With regard to plasma IFN-g, median
values were 91.7, 141.8 and 22.3 pg/ml before and
after 6 and 12 months, respectively. However, these
changes did not reach significance (Fig. 3B).
IL-8 and TNF-a levels were undetectable in plasma
samples of the most patients during all the observa-
tion period (the data are not presented).
Before the treatment the patients demonstrated
relatively low T-cell response to PHA. Clarithromycin
administration resulted in a sustained increase of
peripheral blood lymphocyte proliferation (Table 3).
The most prominent elevation of the cell response to
PHA was revealed 3 months after the start of the
treatment. The same as pro-inflammatory cytokines
(IL-8 and TNF-a) in the sputum, such an increase of
peripheral blood lymphocyte proliferation seems to
be associated with the season changes of inflamma-
tory markers (blood collection was performed in
June). A marked but not so prominent elevation of
FIG. 1. Pulmonary function test results. The data are
presented as mean values of forced vital capacity (FVC)
and forced expiratory volume in 1 sec (FEV1). The results
were analyzed using a paired t-test.
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after 6 and 12 months of the treatment (blood
samples were collected in October and January,
respectively).
IFN-g/IL-4 ratios
The relative concentrations of IFNg and IL-4 were
calculated (Table 4). Prior to treatment, the cytokine
ratios both in sputum and plasma were relatively low
(median values, 1.1 and 2.7, respectively). During 6
months of the treatment the cytokine ratios were
found to be significantly increased (median values,
16.9 and 4.6 in sputum and plasma, respectively).
Over 1 year IFN-g tended to predominate in periph-
eral blood. With regard to cytokine ratios in sputum,
they could not be calculated since the IFN-g level
became undetectable (See Fig. 2C).
FIG. 2. Cytokine concentrations in the sputum during clarithromycin treatment. Sputum specimens were assayed for TNF-a
(A), IL-8 (B), IFN-g (C), and IL-4 (D). Median values are indicated by the lines. Each dot represents one subject. A two-sample
Wilcoxon test was used to compare the cytokine levels before treatment and 3, 6, and 12 months after the start of therapy.
Table 2. Neutrophil elastase activity and protein concentration in the sputa of cystic ﬁbrosis patients during clarithromycin
treatment
Elastase Protein
U/mg protein p mg/ml p
Before treatment 36.4 (0 /1660) 1.5 (0.2 /9.9)
3 months after treatment 39.1 (0 /261.4) 0.28 1.7 (0.1 /6.1) 0.80
6 months after treatment 52.4 (0 /258.9) 0.58 1.7 (0.7 /3.8) 0.40
12 months after treatment 57.2 (0 /260.8) 0.80 1.0 (0.3 /5.3) 0.10
Data are presented as medians (minimum /maximum values). The results were analyzed using a paired Wilcoxon test.
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According to common opinion, the long-term admin-
istration of 14-membered macrolides results in im-
munosuppression. This opinion is supported by in
vitro data of a direct effect on the production of the
cytokines involved in the inflammation cascade
(decreased production of IL-1, IL-6, IL-8 and TNF-a,
and increased production of IL-10)
23 25 and by ex
vivo experiments in animals.
26,27 In our study a
significant decrease of pro-inflammatory IL-8 and
TNF-a in the sputum specimens has been found.
Moreover, a marked reduction of the regulatory
cytokine levels (IL-4 and IFN-g) both in the sputum
and in peripheral blood was demonstrated. At the
same time, the elevation of peripheral blood lym-
phocyte response to PHA has been observed. This
finding contradicts the conclusion about the immu-
nosuppressive effect of long-term macrolide admin-
istration.
From the results reported in the literature, there
appears to be some agreement that chronic treatment
with macrolide antibiotics is effective in cancer.
28,29
This effect is not associated with direct cytotoxic
activity of the drugs, but is a result of enhanced
antitumor immunity. Thus, it has been demonstrated
that only spleen cells obtained from rats that have
been immunized by allogeneic tumor cells followed
by clarithromycin treatment showed a detectable
cytotoxicity to the tumor cells.
30 These data and the
fact that macrolide prescription in DPB patients is not
accompanied by an increase in P. aeruginosa colo-
nization
14 do not support an inference that long-term
administration of these drugs results in imunosup-
pression.
Apparently, the therapeutic effect of macrolides in
patients with lung diseases is associated not only with
the anti-inflammatory activity of the drugs, but with
their immunomodulating properties. Recently, a
modulation of Th2 type cytokine production by
roxithromycin was shown. Thus, this 14-membered
ring macrolide markedly inhibited in vitro both IL-4
and IL-5 secretion by human peripheral blood T cells
in a dose-dependent manner but did not affect T-cell
proliferation induced in several ways including anti-
FIG. 3. Cytokine concentrations in the plasma during clari-
thromycin treatment. Plasma samples were assayed for IL-4
(A) and IFN-g (B). Median values are indicated by the lines.
Each dot represents one subject. A two-sample Wilcoxon
test was used to compare the cytokine levels before treat-
ment and 6 and 12 months after the start of therapy.
Table 3. Effect of clarithromycin treatment on PHA-induced
peripheral blood lymphocyte proliferation
Proliferative response
(counts/min)*
p value
(Student’s
t-test)
Before treatment
(n /25)
186349 /1587
3 months after
treatment (n /25)
753049 /9817 B/0.001
6 months after
treatment (n /20)
396039 /5138 0.001
1 year after treatment
(n /19)
570919 /5622 B/0.001
*Data are presented as the mean9 /standard error of the mean.
Table 4. Changes of IFN-g/IL-4 ratios during clarithromycin treatment
In sputum In plasma
IFN-g/IL-4 p IFN-g/IL-4 p
Before treatment 1.1 (0 /18.9) 2.7 (0 /87.7)
3 months after treatment 0.5 (0 /183.7) 0.32 ND
6 months after treatment 16.9 (0 /131.4) B/0.001 4.6 (0 /798.3) 0.001
12 months after treatment No calculated* 4.4 (0 /2229.0) 0.067
Data are presented as median (minimum /maximum values).
* The ratio could not be calculated since most patients had an undetectable IFN-g level.
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31 Our data are in accor-
dance with these results. Thus, we succeeded in
showing that the long-term clarithromycin treatment
is associated with the change of the IFNg/IL-4 ratio in
favor of IFN-g. Such a shift in the cytokine profile has
been observed both in the sputum and in peripheral
blood. The increase of PHA-stimulated lymphocyte
proliferation has been also demonstrated. This
seemed to be additional evidence of the shift towards
a Th1 type response following clarithromycin treat-
ment. Obviously, the observed immunological
changes are favorable for the patients with CF lung
disease. Thus, in our study a significant increase of
mean FVC and FEV1 during clarithromycin treatment
has been demonstrated. The data are in line with the
results of previous studies showing that a Th1-
dominated immune response might improve the
prognosis obtained in CF patients. In particular, a
positive correlation between IFN-g production and
lung function was found.
32 Similar results have been
obtained in a mouse model of chronic P. aeruginosa
infection, that a more Th1-dominating response
would decrease lung inflammation. The animal
mortality due to the infection was significantly lower
in C3H/HeN mice, known as Th1 responders, com-
pared with BALB/c, known as Th2 responders.
33 It
was also shown that C3H/HeN mice had the highest
IFN-g and the lowest IL-4 production in the lungs
compared with the Th2-reacting BALB/c mice.
34
In conclusion, the beneficial effect of the pro-
longed treatment of CF patients with a 14-membered
ring macrolide antibiotic, clarithromycin, seems to be
associated not only with down-regulation of the
inflammatory response, but also with immunological
changes including the switch from Th2 to Th1 type
response.
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